Pharm-Olam is now Allucent. Learn More
A Pharm-Olam case study of a Phase I/II pediatric Respiratory Distress Syndrome neonate study with a gestational age between 27 and 33 weeks.
2 min. Read
In this Phase III study, Pharm-Olam partnered with a progressive sponsor company to assist in finding a better solution for suffering with ...
3 min. read
Pharm-Olam provided a complete enrollment solution for the management and data submission of this Acute Bacterial Skin and Skin Structure ...
2 min. Read
A Pharm-Olam overview of Allergic Rhinitis based on two decades of study experience.
2 min. read
In this ebook, we discuss clinical trial best practices in Allergy and Asthma as well as new research in 2021.
10 min. Read
In this white paper we cover key events in lupus history as well as the current ...
10 min. Read
We'll only send you one email a month featuring our best content from the month before.
Subscribe to the Learning Center
